These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9269497)

  • 1. Use of nonlinear mixed effects modelling in the development of in vitro-in vivo correlations.
    Bigora S; Piscitelli D; Dowell J; Butler J; Farrell C; Devane J; Young D
    Adv Exp Med Biol; 1997; 423():207-15. PubMed ID: 9269497
    [No Abstract]   [Full Text] [Related]  

  • 2. Approaches to IVIVR modelling and statistical analysis.
    Dunne A; O'Hara T; Devane J
    Adv Exp Med Biol; 1997; 423():67-86. PubMed ID: 9269484
    [No Abstract]   [Full Text] [Related]  

  • 3. Nonlinear in vitro-in vivo correlations.
    Mendell-Harary J; Dowell J; Bigora S; Piscitelli D; Butler J; Farrell C; Devane J; Young D
    Adv Exp Med Biol; 1997; 423():199-206. PubMed ID: 9269496
    [No Abstract]   [Full Text] [Related]  

  • 4. Artificial neural network based in vitro-in vivo correlations.
    Hussain AS
    Adv Exp Med Biol; 1997; 423():149-58. PubMed ID: 9269490
    [No Abstract]   [Full Text] [Related]  

  • 5. Development of in vitro-in vivo correlations using various artificial neural network configurations.
    Dowell JA; Hussain AS; Stark P; Devane J; Young D
    Adv Exp Med Biol; 1997; 423():225-39. PubMed ID: 9269500
    [No Abstract]   [Full Text] [Related]  

  • 6. A new approach to modelling the relationship between in vitro and in vivo drug dissolution/absorption.
    Dunne A; O'Hara T; Devane J
    Stat Med; 1999 Jul; 18(14):1865-76; discussion 1877. PubMed ID: 10407257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of covariance between random effects in design for nonlinear mixed-effect models with an illustration in pediatric pharmacokinetics.
    Dumont C; Chenel M; Mentré F
    J Biopharm Stat; 2014; 24(3):471-92. PubMed ID: 24697342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Goal-oriented, model-based drug regimens.
    Jelliffe RW; Maire P
    Comput Biol Med; 2001 May; 31(3):145-6. PubMed ID: 11173052
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of robust criteria for D-optimal designs.
    Foo LK; McGree J; Eccleston J; Duffull S
    J Biopharm Stat; 2012; 22(6):1193-205. PubMed ID: 23075017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissolution assay development for in vitro-in vivo correlations. Theory and case studies.
    Rohrs BR; Skoug JW; Halstead GW
    Adv Exp Med Biol; 1997; 423():17-30. PubMed ID: 9269480
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro-in vivo relationships for oral extended-release drug products.
    Mauger DT; Chinchilli VM
    J Biopharm Stat; 1997 Nov; 7(4):565-78. PubMed ID: 9358329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of in vitro-in vivo correlation models.
    Young D; Dowell JA; Piscitelli DA; Devane J
    Adv Exp Med Biol; 1997; 423():87-91. PubMed ID: 9269485
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of methodologies for evaluating regional intestinal permeability.
    Raoof A; Moriarty D; Brayden D; Corrigan OI; Cumming I; Butler J; Devane J
    Adv Exp Med Biol; 1997; 423():181-9. PubMed ID: 9269494
    [No Abstract]   [Full Text] [Related]  

  • 14. [Comparison study of model evaluation methods: normalized prediction distribution errors vs. visual predictive check].
    Ren YP; Deng CH; Wang XP; Zhou TY; Lu W
    Yao Xue Xue Bao; 2011 Sep; 46(9):1123-31. PubMed ID: 22121786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A point estimator for the time course of drug release.
    Koehne-Voss S; Pigeot I
    Biom J; 2009 Feb; 51(1):146-58. PubMed ID: 19219906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methods of robust design of nonlinear models with an application to pharmacokinetics.
    Foo LK; Duffull S
    J Biopharm Stat; 2010 Jul; 20(4):886-902. PubMed ID: 20496212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Examples of developing in vitro-in vivo relationships.
    Butler J
    Adv Exp Med Biol; 1997; 423():93-110. PubMed ID: 9269486
    [No Abstract]   [Full Text] [Related]  

  • 18. IVIVC of controlled release formulations: physiological-dynamical reasons for their failure.
    Dokoumetzidis A; Macheras P
    J Control Release; 2008 Jul; 129(2):76-8. PubMed ID: 18538435
    [No Abstract]   [Full Text] [Related]  

  • 19. Transform-both-sides nonlinear models for in vitro pharmacokinetic experiments.
    Latif AH; Gilmour SG
    Stat Methods Med Res; 2015 Jun; 24(3):306-24. PubMed ID: 25038072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Issues important to in vitro-in vivo correlation. IVIVR Workshop open discussion.
    Adv Exp Med Biol; 1997; 423():289-95. PubMed ID: 9269504
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.